Catalog No.
PVV03201
Species reactivity
Human immunodeficiency virus 2 (HIV-2)
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant HIV-2 env/Env polyprotein/gp36 (Gln547-Tyr670).
Target
Envelope glycoprotein gp160, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, env
Purification
Purified by antigen affinity column.
Accession
L8B302
Applications
ELISA, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates., PMID:37240423
Cryo-EM structures of prefusion SIV envelope trimer., PMID:36344847
HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs., PMID:35563157
Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy., PMID:34821542
Selection and immune recognition of HIV-1 MPER mimotopes., PMID:32980676
eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody., PMID:31068428
Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein-Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2-Infected Individuals., PMID:30715363
Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11., PMID:29618644
eCD4-Ig Variants That More Potently Neutralize HIV-1., PMID:29593050
Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability., PMID:27064278
Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors., PMID:27058352
Structure of an HIV-2 gp120 in Complex with CD4., PMID:26608312
Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its ability to detect HIV gp41 IgM antibodies., PMID:26311612
NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles., PMID:25700718
Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency., PMID:25673728
[Use of a synthetic peptide of HIV-2 glycoprotein 36 in antigen mixtures for the immunodiagnosis of HIV types 1 and 2]., PMID:25639906
Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA., PMID:25514675
[Development of an antigen 'sandwich' enzyme immunoassay for the detection of antibodies against HIV-2 by using a biotinylated synthetic peptide of gp36 protein]., PMID:25482431
How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses?, PMID:25445493
Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family., PMID:24970741
Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals., PMID:24909946
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity., PMID:24352444
Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response., PMID:24156513
Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism., PMID:23151495
A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity., PMID:23147734
Designing of novel antigenic peptide cocktail for the detection of antibodies to HIV-1/2 by ELISA., PMID:23098841
HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug., PMID:22615295
Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein., PMID:22291921
Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes., PMID:22072758
Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection., PMID:22031948
Comparison of alternative interpretive criteria for the HIV-1 Western blot and results of the Multispot HIV-1/HIV-2 Rapid Test for classifying HIV-1 and HIV-2 infections., PMID:21993309
Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors., PMID:21902586
Frequency of human immunodeficiency virus type-2 in hiv infected patients in Maputo City, Mozambique., PMID:21849066
Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125., PMID:21541316
Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection., PMID:21283793
A highly sensitive and specific time resolved fluorometric bridge assay for antibodies to HIV-1 and -2., PMID:21232554
Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105., PMID:21175253
Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy., PMID:20844029
Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity., PMID:20357769
4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms., PMID:20352106
Molecular epidemiology of HIV type 2 infections in South India., PMID:19327056
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination., PMID:19298995
Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen., PMID:19084043
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma., PMID:19019969
Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression., PMID:18981765
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C., PMID:18815292
The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients., PMID:18778482
HIV-2 neutralization by intact V3-specific Fab fragments., PMID:18706111
HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane., PMID:18191596
The immunogenic CBD1 peptide corresponding to the caveolin-1 binding domain in HIV-1 envelope gp41 has the capacity to penetrate the cell membrane and bind caveolin-1., PMID:18054388
For research use only. Not for human or drug use.
